{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:19:26Z","timestamp":1793283566488,"version":"4.5.0"},"reference-count":202,"publisher":"Elsevier","isbn-type":[{"value":"9780128152133","type":"print"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1016\/bs.pmch.2017.12.001","type":"book-chapter","created":{"date-parts":[[2018,3,13]],"date-time":"2018-03-13T20:55:30Z","timestamp":1520974530000},"page":"1-86","source":"Crossref","is-referenced-by-count":38,"title":["Discovery and Development of Calcimimetic and Calcilytic Compounds"],"prefix":"10.1016","author":[{"given":"Edward F.","family":"Nemeth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradford C.","family":"Van Wagenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel F.","family":"Balandrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/bs.pmch.2017.12.001_bb0010","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.beem.2013.02.006","article-title":"Role of the calcium-sensing receptor in extracellular calcium homeostasis","volume":"27","author":"Brown","year":"2013","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0015","series-title":"Principles of bone biology","first-page":"1019","article-title":"Calcium receptors as novel drug targets","author":"Nemeth","year":"1996"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0020","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1196\/annals.1346.044","article-title":"Misconceptions about calcimimetics","volume":"1068","author":"Nemeth","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0025","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3389\/fphys.2016.00563","article-title":"The calcium-sensing receptor and the parathyroid: past, present, future","volume":"7","author":"Conigrave","year":"2016","journal-title":"Front Physiol"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0030","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.beem.2013.04.007","article-title":"Calcium-sensing receptor (CaSR) mutations and disorders of calcium, electrolyte and water metabolism","volume":"27","author":"Hannan","year":"2013","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0035","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1085\/jgp.82.2.269","article-title":"Depolarizing response of rat parathyroid cells to divalent cations","volume":"82","author":"Lopez-Barneo","year":"1983","journal-title":"J Gen Physiol"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0040","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0014-5793(86)81427-2","article-title":"Cytosolic Ca2+ and the regulation of secretion in parathyroid cells","volume":"203","author":"Nemeth","year":"1986","journal-title":"FEBS Lett"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0045","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/0014-5793(86)80880-8","article-title":"Calcium-activated calcium permeability in parathyroid cells","volume":"205","author":"Gylfe","year":"1986","journal-title":"FEBS Lett"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0050","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1016\/S0021-9258(18)61172-X","article-title":"Rapid mobilization of cellular Ca2+ in bovine parathyroid cells evoked by extracellular divalent cations. Evidence for a cell surface calcium receptor","volume":"262","author":"Nemeth","year":"1987","journal-title":"J Biol Chem"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0055","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0143-4160(90)90033-Q","article-title":"Regulation of cytosolic calcium by extracellular divalent cations in C-cells and parathyroid cells","volume":"11","author":"Nemeth","year":"1990","journal-title":"Cell Calcium"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0060","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0014-5793(87)81029-3","article-title":"High extracellular Ca2+ and Mg2+ stimulate accumulation of inositol phosphates in bovine parathyroid cells","volume":"218","author":"Brown","year":"1987","journal-title":"FEBS Lett"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0065","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1210\/endo-123-1-382","article-title":"High calcium and other divalent cations increase inositol trisphosphate in bovine parathyroid cells","volume":"123","author":"Shoback","year":"1988","journal-title":"Endocrinology"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0070","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1210\/endo-124-2-789","article-title":"The effects of protein kinase-C agonists on parathyroid hormone release and intracellular free Ca2+ in bovine parathyroid cells","volume":"124","author":"Membre\u00f1o","year":"1989","journal-title":"Endocrinology"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0075","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1113\/jphysiol.1993.sp019765","article-title":"Protein kinase C modulates hormone secretion regulated by extracellular polycations in bovine parathyroid cells","volume":"468","author":"Racke","year":"1993","journal-title":"J Physiol"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0080","first-page":"14a","article-title":"Mobilization of intracellular calcium and inhibition of hormone secretion in parathyroid cells by fluoride","volume":"92","author":"Nemeth","year":"1988","journal-title":"J Gen Physiol"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0085","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1210\/endo-122-6-2833","article-title":"Fluoride stimulates the accumulation of inositol phosphates, increases intracellular free calcium, and inhibits parathyroid hormone release in dispersed bovine parathyroid cells","volume":"122","author":"Shoback","year":"1988","journal-title":"Endocrinology"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0090","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1210\/endo-124-1-233","article-title":"Divalent cations suppress 3\u2032,5\u2032-adenosine monophosphate accumulation by stimulating a pertussis toxin-sensitive guanine nucleotide-binding protein in cultured bovine parathyroid cells","volume":"124","author":"Chen","year":"1989","journal-title":"Endocrinology"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0095","series-title":"Calcium-binding proteins in health and disease","first-page":"33","article-title":"Spermine evokes the rapid mobilization of cellular Ca2+ in parathyroid cells","author":"Nemeth","year":"1987"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0100","unstructured":"Nemeth EF, Van Wagenen BC, Balandrin MF, DelMar EG, Moe ST; NPS Pharmaceuticals, Inc., USA. Calcium receptor-active molecules. US6031003;2000"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0105","doi-asserted-by":"crossref","first-page":"C1315","DOI":"10.1152\/ajpcell.1997.273.4.C1315","article-title":"The Ca2+-sensing receptor: a target for polyamines","volume":"273","author":"Quinn","year":"1997","journal-title":"Am J Physiol"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0110","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1210\/endo-128-6-3047","article-title":"Neomycin mimics the effects of high extracellular calcium concentrations on parathyroid function is dispersed bovine parathyroid cells","volume":"128","author":"Brown","year":"1991","journal-title":"Endocrinology"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0115","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/jbmr.5650061112","article-title":"Polyarginine, polylysine, and protamine mimic the effects of high extracellular calcium concentrations on dispersed bovine parathyroid cells","volume":"6","author":"Brown","year":"1991","journal-title":"J Bone Miner Res"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0120","series-title":"Neuroreceptors, ion channels and the brain","first-page":"21","article-title":"Arylamines derived from spider venom are potent and selective NMDA receptor antagonists in the mammalian CNS","author":"Nemeth","year":"1992"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0125","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1056\/NEJMp048153","article-title":"Translational implications of the parathyroid calcium receptor","volume":"351","author":"Stewart","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0130","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S0006-291X(86)80589-7","article-title":"Control of PTH secretion is mediated through calcium channels and is blocked by pertussis toxin treatment in parathyroid cells","volume":"138","author":"Fitzpatrick","year":"1986","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0135","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/0003-9861(88)90378-5","article-title":"Regulation of hormone secretion and cytosolic Ca2+ by extracellular Ca2+ in parathyroid cells and C-cell: role of voltage-sensitive Ca2+ channels","volume":"265","author":"Muff","year":"1988","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0140","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0167-4889(85)90029-1","article-title":"Paradoxical effects of K+ and D-600 on parathyroid hormone secretion and cytoplasmic Ca2+ in normal bovine and pathological human parathyroid cells","volume":"847","author":"Larsson","year":"1985","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0145","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1016\/j.ddtec.2012.11.002","article-title":"Allosteric modulators of the extracellular calcium receptor","volume":"10","author":"Nemeth","year":"2013","journal-title":"Drug Discov Today Technol"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0150","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/366575a0","article-title":"Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid","volume":"366","author":"Brown","year":"1993","journal-title":"Nature"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0155","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.pharmthera.2010.04.007","article-title":"Broad-spectrum amino acid-sensing class C G-protein coupled receptors: molecular mechanisms, physiological significance and options for drug development","volume":"127","author":"Conigrave","year":"2010","journal-title":"Pharmacol Ther"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0160","doi-asserted-by":"crossref","first-page":"12919","DOI":"10.1074\/jbc.270.21.12919","article-title":"Molecular cloning and functional expression of human parathyroid calcium receptor cDNAs","volume":"270","author":"Garrett","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0165","unstructured":"Harootunian AT; NPS Pharmaceuticals, Inc., USA. Fluorescence detection apparatus. US5589351;1996"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0170","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1113\/jphysiol.1910.sp001392","article-title":"Chemical structure and sympathomimetic action of amines","volume":"41","author":"Barger","year":"1910","journal-title":"J Physiol"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0175","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1073\/pnas.95.7.4040","article-title":"Calcimimetics with potent and selective activity on the parathyroid calcium receptor","volume":"95","author":"Nemeth","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0180","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1210\/jcem.83.4.4726","article-title":"Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent","volume":"83","author":"Collins","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0185","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1046\/j.1523-1755.1998.00735.x","article-title":"A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure","volume":"53","author":"Antonsen","year":"1998","journal-title":"Kidney Int"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0190","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1046\/j.1523-1755.2000.00183.x","article-title":"A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism","volume":"58","author":"Goodman","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0195","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199711203372104","article-title":"Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism","volume":"337","author":"Silverberg","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0200","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/00008571-200110000-00004","article-title":"Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6","volume":"11","author":"Zanger","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0205","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.clpt.2003.12.003","article-title":"Human liver cytochrome P450 2D6 genotype, full-length messenger ribonucleic acid, and activity assessed with a novel P450 2D6 substrate","volume":"75","author":"McConnachie","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0210","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2215\/CJN.06040710","article-title":"Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options","volume":"6","author":"Cunningham","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0215","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/00041552-199907000-00006","article-title":"The calcium receptor and calcimimetics","volume":"8","author":"Wada","year":"1999","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0220","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.pharmthera.2005.06.019","article-title":"Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism","volume":"109","author":"Nagano","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0225","series-title":"Principles of bone biology","first-page":"1711","article-title":"Drugs acting on the calcium receptor. Calcimimetics and calcilytics","author":"Nemeth","year":"2008"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0230","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/jbmr.1869","article-title":"Calcitonin: physiology or fantasy?","volume":"28","author":"Davey","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0235","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0022-3565(24)34925-0","article-title":"Calcimimetic compound NPS R-568 stimulates calcitonin secretion but selectively targets parathyroid gland Ca2+ receptor in rats","volume":"290","author":"Fox","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0240","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1210\/endo.136.11.7588259","article-title":"Calcitonin-secreting cells of the thyroid express an extracellular calcium receptor gene","volume":"136","author":"Garrett","year":"1995","journal-title":"Endocrinology"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0245","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1124\/dmd.104.000604","article-title":"Metabolism and disposition of calcimimetic agent cinacalcet HCl in humans and animal models","volume":"32","author":"Kumar","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0250","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1124\/jpet.103.057273","article-title":"Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl","volume":"308","author":"Nemeth","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0255","series-title":"The spectrum of mineral and bone disorders in chronic kidney disease","first-page":"443","article-title":"Calcimimetics and calcilytics in the treatment of chronic kidney disease-mineral and bone disorder","author":"Nemeth","year":"2010"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0260","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1681\/ASN.2007121320","article-title":"Cinacalcet reduces the set point of the PTH-calcium curve","volume":"19","author":"Valle","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0265","article-title":"Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients (review)","volume":"12","author":"Ballinger","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0270","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2215\/CJN.01760215","article-title":"Clinical and practical use of calcimimetics in dialysis patients with secondary hyperparathyroidism","volume":"11","author":"Bover","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0275","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3109\/0886022X.2016.1172468","article-title":"Cinacalcet versus standard treatment for chronic kidney disease: a systematic review and meta-analysis","volume":"38","author":"Sekercioglu","year":"2016","journal-title":"Ren Fail"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0280","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/01213011-200501000-00005","article-title":"Calcium-sensing receptor gene polymorphism Arg990Gly and its possible effect on response to cinacalcet HCl","volume":"15","author":"Rothe","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0285","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.beem.2013.02.008","article-title":"Calcimimetic and calcilytic drugs for treating bone and mineral-related diorders","volume":"27","author":"Nemeth","year":"2013","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0290","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1053\/j.ajkd.2008.09.021","article-title":"A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis","volume":"53","author":"Chonchol","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0295","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1053\/j.ajkd.2005.04.013","article-title":"Cinacalcet hydrochloride is an effective treatment for seconday hperparathyroidism in patients with CKD not receiving dialysis","volume":"46","author":"Charytan","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0300","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","article-title":"The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis","volume":"26","author":"Raggi","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0305","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"EVOLVE Trial Investigators","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0310","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/CIRCULATIONAHA.114.013876","article-title":"Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis","volume":"132","author":"Moe","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0315","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/jhh.2015.56","article-title":"The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial","volume":"30","author":"Chang","year":"2016","journal-title":"J Hum Hypertens"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0320","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001363","article-title":"Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the Evaluation of cinacalcet HCl therapy to lower Cardiovascular events (EVOLVE) trial","volume":"3","author":"Wheeler","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0325","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/ki.2014.349","article-title":"Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism","volume":"87","author":"Behets","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0330","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1681\/ASN.2014040414","article-title":"Effects of cinacalcet on fracture events in patients receiving hemodialysis: the EVOLVE trial","volume":"26","author":"Moe","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0335","doi-asserted-by":"crossref","first-page":"R127","DOI":"10.1530\/JME-16-0124","article-title":"Disorders of the calcium-sensing receptor and partner proteins: insights into the molecular basis of calcium homeostasis","volume":"57","author":"Hannan","year":"2016","journal-title":"J Mol Endocrinol"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0340","doi-asserted-by":"crossref","DOI":"10.1111\/bph.14086","article-title":"Calcimimetic and calcilytic therapies for inherited disorders of the calcium-sensing receptor signalling pathway","author":"Hannan","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0345","unstructured":"Van Wagenen BC, Moe ST, Balandrin MF, DelMar EG, Nemeth EF; NPS Pharmaceuticals, Inc., USA. Calcium receptor-active molecules. US6211244B1;2001."},{"key":"10.1016\/bs.pmch.2017.12.001_bb0350","unstructured":"Hachiya S, Oku M, Mukai H, Shin T, Matsuura K, Seo R, Kamikubo T, Terada Y, Sanagi M, Yoshihara K, Takahashi T; Astellas Pharma Inc., Japan. Pyrrolidine derivative or salt thereof. US758588B2;2009."},{"key":"10.1016\/bs.pmch.2017.12.001_bb0355","unstructured":"Hachiya S, Ikegai K, Ibuka R, Takahashi T, Oku M, Seo R, Terada Y, Sanagi M. Astellas Pharma Inc., Japan. Piperidine derivative or salt thereof. US2010\/0029687A1;2010"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0360","author":"NCT02133404"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0365","unstructured":"Ebdrup S, Nielsen KT, Greve TM; Leo Pharma A\/S, Denmark. Polymorphic form of a calcimimetic compound. US8946474B2;2015"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0370","unstructured":"Norremark B, Blaehr LKA, Knapp AE, Mansson K; Leo Pharma A\/S, Denmark. Calcium sensing receptor modulating compounds and pharmaceutical use thereof. US8765676B2;2014"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0375","unstructured":"Norremark B; Leo Pharma A\/S, Denmark. Calcium sensing receptor modulating compounds and pharmaceutical use thereof. US8785494B2;2014"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0380","author":"NCT01143298"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0385","author":"NCT01167309"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0390","unstructured":"Miyazaki H, Tsubakimoto J, Yasuda K, Takamuro I, Sakurai O, Yanagida T, Hisada Y; Tanabe Seiyaku Co. Ltd, Japan. Arylalkylamines and process for production thereof. EP1757582A1;2005"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0395","article-title":"The novel calcimimetic agent evocalcet (MT-4580\/KHK7580) has a potential for the treatment of hyperparathyroidism with less effect on the gastrointestinal motility in vivo models","author":"Tokunaga","year":"2017","journal-title":"Ann Meeting Am Soc Nephrol"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0400","author":"Kyowa Hakko Kirin press release"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0405","author":"Kyowa Hakko Kirin press release"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0410","author":"Kyowa Hakko Kirin press release"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0415","doi-asserted-by":"crossref","first-page":"5544","DOI":"10.1016\/j.bmcl.2010.07.060","article-title":"The discovery of an orally efficacious positive allosteric modulator of the calcium sensing receptor containing a dibenzylamine core","volume":"20","author":"Harrington","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0420","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1124\/jpet.110.178681","article-title":"Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion","volume":"337","author":"Henly","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0425","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1038\/sj.ki.5001888","article-title":"Calcitonin concentrations in patients with chronic kidney disease and medullary thyroid carcinoma or C-cell hyperplasia","volume":"70","author":"Borchhardt","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0430","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ejphar.2009.05.013","article-title":"The calcimimetic AMG 641 abrogates parathyroid hyperplasia, bone and vascular calcification abnormalities in uremic rats","volume":"616","author":"Henley","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0435","doi-asserted-by":"crossref","first-page":"6535","DOI":"10.1021\/jm9012278","article-title":"Discovery and optimization of substituted 1-(1-phenyl-1H-pyrazol-3-yl)methanamines as potent and efficacious type II calcimimetics","volume":"52","author":"Poon","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0440","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0960-894X(00)00382-6","article-title":"N1-Arylsulfonyl-N2-(1-aryl)ethyl-3-phenylpropane-1,2-diamines","volume":"10","author":"Dauban","year":"2000","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0445","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1016\/j.bmcl.2004.03.056","article-title":"N2-Benzyl-N1-(1-(naphthyl)ethyl)-3-phenylpropane-1,2-diamines and conformationally restrained indole analogues: development of calindol as a new calcimimetic acting at the calcium sensing receptor","volume":"14","author":"Kessler","year":"2004","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0450","first-page":"245","article-title":"The extracellular calcium-sensing receptor in the intestine: evidence for regulation of colonic absorption, secretion, motility, and immunity","volume":"7","author":"Tang","year":"2016","journal-title":"Front Physiol"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0455","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.155","article-title":"Pharmacology and physiology of gastrointestinal enteroendocrine cells","volume":"3","author":"Mace","year":"2015","journal-title":"Pharmacol Res Perspect"},{"issue":"20","key":"10.1016\/bs.pmch.2017.12.001_bb0460","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1016\/j.bmcl.2017.09.008","article-title":"Identification of potent, nonabsorbable agonists of the calcium-sensing receptor for GI-specific administration","author":"Sparks","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0465","doi-asserted-by":"crossref","first-page":"7922","DOI":"10.1039\/c2ob26402a","article-title":"Allosteric agonists of the calcium receptor (CaR): fluorine and SF5 analogues of cinacalcet","volume":"10","author":"Chia","year":"2012","journal-title":"Org Biomol Chem"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0470","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1080\/14656566.2017.1303482","article-title":"Etelcalcetide for the treatment of secondary hyperparathyroidism","volume":"18","author":"Hamano","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0475","unstructured":"Karim F, Baruch A, MaClean D; KAI Pharmaceuticals, Inc., USA. Therapeutic agents for reducing parathyroid hormone levels. US2011\/0028394A1;2011."},{"key":"10.1016\/bs.pmch.2017.12.001_bb0480","first-page":"853","article-title":"Critical cysteine residues in both the calcium-sensing receptor and the allosteric activator AMG 416 underlie the mechanism of action","volume":"88","author":"Alexander","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0485","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/jpet.113.204834","article-title":"Pharmacology of AMG 416 (velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients","volume":"346","author":"Walter","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0490","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1124\/dmd.115.068007","article-title":"Nonclinical pharmacokinetics, disposition, and drug-drug interaction potential of a novel D-amino acid peptide agonist of the calcium-sensing receptor AMG 416 (etelcalcetide)","volume":"44","author":"Subramanian","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0495","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/1091581816633407","article-title":"Nonclinical safety profile of etelcalcetide, a novel peptide calcimimetic for the treatment of secondary hyperparathyroidism","volume":"35","author":"Fielden","year":"2016","journal-title":"Int J Toxicol"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0500","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40262-016-0433-0","article-title":"Pharmacokinetics, biotransformation, and excretion of [14C]etelcalcetide (AMG 416) following a single microtracer intravenous dose in patients with chronic kidney disease on hemodialysis","volume":"56","author":"Subramanian","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0505","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/jcph.314","article-title":"A pharmacokinetic\/pharmacodynamic model for AMG 416, a novel calcimimetic peptide, following a single intravenous dose in healthy subjects","volume":"54","author":"Shen","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0510","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ekir.2016.04.002","article-title":"Determination of etelcalcetide biotransformation and hemodialysis kinetics to guide the timing of its dosing","volume":"1","author":"Edson","year":"2016","journal-title":"Kidney Int Rep"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0515","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/ndt\/gft417","article-title":"Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF-23 levels in healthy male subjects","volume":"29","author":"Martin","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0520","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1159\/000442754","article-title":"Treatment of secondary hyperparathyroidism: results of a phase 2 trial evaluating an intravenous peptide agonist of the calcium-sensing receptor","volume":"42","author":"Bushinsky","year":"2015","journal-title":"Am J Nephrol"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0525","first-page":"1723","volume":"32","author":"Fukagawa","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0530","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/jama.2016.19456","article-title":"Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism. Two randomized clinical trials","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0535","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jim.2017.03.005","article-title":"Clinical immunogenicity of the D-amino acid peptide therapeutic etelcalcetide: method development challenges and anti-drug antibody clinical impact assessments","volume":"445","author":"Kroenke","year":"2017","journal-title":"J Immunol Methods"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0540","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jama.2016.19468","article-title":"Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism. A randomized clinical trial","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0545","first-page":"2132","article-title":"Dosing of etelcalcetide and cinacalcet for secondary hyperparathyroidism","volume":"317","author":"Thanh Hai","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0550","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.bmcl.2013.01.078","article-title":"New potent calcimimetics: I. Discovery of a series of novel trisubstituted ureas","volume":"23","author":"Temal","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0555","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1016\/j.bmcl.2013.01.077","article-title":"New potent calcimimetics: II. Discovery of benzothiazole trisubstituted ureas","volume":"23","author":"Deprez","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0560","doi-asserted-by":"crossref","first-page":"6625","DOI":"10.1016\/j.bmcl.2013.10.050","article-title":"Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidism","volume":"23","author":"Wehn","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0565","doi-asserted-by":"crossref","first-page":"5918","DOI":"10.1016\/j.bmcl.2010.07.077","article-title":"Discovery of a class of calcium sensing receptor positive allosteric modulators; 1-(benzothiazol-2-yl)-1-phenylethanols","volume":"20","author":"Gustafsson","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0570","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1124\/jpet.110.178194","article-title":"Characterization of highly efficacious allosteric agonists of the human calcium-sensing receptor","volume":"337","author":"Ma","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0575","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1073\/pnas.97.9.4814","article-title":"L-Amino acid sensing by the extracellular Ca2+-sensing receptor","volume":"97","author":"Conigrave","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0580","first-page":"G753","article-title":"Taste receptors in the gastrointestinal tract II. L-Amino acid sensing by calcium-sensing receptors: implications for GI physiology","volume":"291","author":"Conigrave","year":"2006","journal-title":"Am J Physiol"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0585","doi-asserted-by":"crossref","first-page":"8864","DOI":"10.1074\/jbc.M512865200","article-title":"Activation of family C G-protein-coupled receptors by the tripeptide glutathione","volume":"281","author":"Wang","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0590","doi-asserted-by":"crossref","first-page":"8786","DOI":"10.1074\/jbc.M110.149724","article-title":"Allosteric modulation of the calcium-sensing receptor by \u03b3-glutamyl peptides","volume":"286","author":"Broadhead","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0595","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.phrs.2013.11.006","article-title":"Pharmacoperones and the calcium-sensing receptor: exogenous and endogenous regulators","volume":"83","author":"Breitwieser","year":"2014","journal-title":"Pharmacol Res"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0600","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0034489","article-title":"Kokumi substances, enhancers of basic tastes, induce responses in calcium-sensing receptor expressing taste cells","volume":"7","author":"Maruyama","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0605","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1074\/jbc.M109.029165","article-title":"Involvement of the calcium-sensing receptor in human taste perception","volume":"285","author":"Ohsu","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0610","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1248\/cpb.c16-00293","article-title":"Structure-CaSR-activity relation of Kokumi \u03b3-glutamyl peptides","volume":"64","author":"Amino","year":"2016","journal-title":"Chem Pharm Bull"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0615","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.coph.2015.03.005","article-title":"Parathyroid hormone: anabolic and catabolic actions on the skeleton","volume":"22","author":"Silve","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0620","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1138\/20080318","article-title":"Anabolic therapy for osteoporosis: calcilytics","volume":"5","author":"Nemeth","year":"2008","journal-title":"IBMS BoneKEy"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0625","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1677\/jme.0.0290015","article-title":"The search for calcium receptor antagonists (calcilytics)","volume":"29","author":"Nemeth","year":"2002","journal-title":"J Mol Endocrinol"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0630","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1021\/jm900364m","article-title":"Antagonists of the calcium receptor I. Amino alcohol-based parathyroid hormone secretagogues","volume":"52","author":"Marquis","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0635","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0022-3565(24)29333-2","article-title":"Calcilytic compounds: potent and selective Ca2+ receptor antagonists that stimulate secretion of parathyroid hormone","volume":"299","author":"Nemeth","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0640","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1172\/JCI9038","article-title":"Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats","volume":"105","author":"Gowen","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0645","doi-asserted-by":"crossref","first-page":"6599","DOI":"10.1021\/jm900563e","article-title":"Antagonists of the calcium receptor. 2. Amino alcohol-based parathyroid hormone secretagogues","volume":"52","author":"Marquis","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0650","unstructured":"Lago MA, Callahan JF, Bhatnagar PK, Del Mar RG, Bryan WM, Burgess JL; SmithKline Beecham Corporation, NPS Pharmaceuticals, Inc., USA. Calcilytic compounds. US7109238B2;2006"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0655","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.bone.2009.09.028","article-title":"An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation","volume":"46","author":"Kumar","year":"2010","journal-title":"Bone"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0660","unstructured":"Marquis RW, Casillas LN, Ramanjulu JM, Callahan JF; GlaxoSmithKline, LLC, USA. Calcilytic compounds. US7514473B2;2009"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0665","unstructured":"Marquis RW, Casillas LN, Ramanjulu JM, Callahan JF; GlaxoSmithKline, LLC, USA. Calcilytic compounds. US7829594B2;2010"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0670","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1016\/j.bmcl.2010.04.035","article-title":"New aminopropandiol derivatives as orally available and short-acting calcium-sensing receptor antagonists","volume":"20","author":"Shinagawa","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0675","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1021\/ml100268k","article-title":"Discovery of a potent and short-acting oral calcilytic with a pulsatile secretion of parathyroid hormone","volume":"2","author":"Shinagawa","year":"2010","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0680","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ejphar.2011.07.015","article-title":"JTT-305, an orally active calcium-sensing receptor antagonist, stimulates transient parathyroid hormone release and bone formation in ovariectomized rats","volume":"668","author":"Kimura","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0685","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.bone.2012.03.004","article-title":"Pharmacodynamic responses to combined treatment regimens with the calcium sensing receptor antagonist JTT-305\/MK-5442 and alendronate in osteopenic ovariectomized rats","volume":"50","author":"Fisher","year":"2012","journal-title":"Bone"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0690","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1016\/j.bmcl.2009.04.044","article-title":"The discovery of novel calcium sensing receptor negative allosteric modulators","volume":"19","author":"Balan","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0695","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1021\/ml100058w","article-title":"Metabolism-guided design of short-acting calcium-sensing receptor antagonists","volume":"1","author":"Southers","year":"2010","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0700","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1016\/j.bmcl.2016.06.073","article-title":"Discovery of novel dihydrobenzofuran cyclopropane carboxylic acid based calcium sensing receptor antagonists for the treatment of osteoporosis","volume":"26","author":"Liang","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0705","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.bmcl.2004.11.071","article-title":"Discovery and structure-activity relationships of 2-benzylpyrrolidine-substituted aryloxypropanols as calcium-sensing receptor antagonists","volume":"15","author":"Yang","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0710","doi-asserted-by":"crossref","first-page":"5478","DOI":"10.1016\/j.bmcl.2005.08.095","article-title":"Discovery of novel 1-arylmethyl pyrrolidin-2-yl ethanol amines as calcium-sensing receptor antagonists","volume":"15","author":"Gavai","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0715","doi-asserted-by":"crossref","first-page":"5161","DOI":"10.1016\/j.bmcl.2010.07.016","article-title":"Penta-substituted benzimidazoles as potent antagonists of the calcium-sensing receptor (CaSR-antagonists)","volume":"20","author":"Gerspacher","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0720","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1021\/jm901811v","article-title":"1-Alkyl-4-phenyl-6-alkoxy-1H-quinazolin-2-ones: a novel series of potent calcium-sensing receptor antagonists","volume":"53","author":"Widler","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0725","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.bone.2011.04.007","article-title":"ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans","volume":"49","author":"John","year":"2011","journal-title":"Bone"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0730","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.bone.2014.04.015","article-title":"AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women","volume":"64","author":"John","year":"2014","journal-title":"Bone"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0735","doi-asserted-by":"crossref","first-page":"535","DOI":"10.4155\/fmc.11.17","article-title":"Calcilytics: antagonists of the calcium-sensing receptor for the treatment of osteoporosis","volume":"3","author":"Widler","year":"2011","journal-title":"Future Med Chem"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0740","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.bmcl.2005.01.078","article-title":"3H-Quinazolin-4-ones as a new calcilytic template for the potential treatment of osteoporosis","volume":"15","author":"Shcherbakova","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0745","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1016\/j.bmcl.2009.07.004","article-title":"Short-acting 5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as orally-active calcium-sensing receptor antagonists","volume":"19","author":"Didiuk","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0750","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1021\/tx100137n","volume":"23","author":"Kalgutkar","year":"2010","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0755","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.bmcl.2005.03.054","article-title":"Design, new synthesis, and calcilytic activity of substituted 3H-pyrimidin-4-ones","volume":"15","author":"Shcherbakova","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0760","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1021\/jm801178c","article-title":"Discovery and structure-activity relationships of trisubstituted pyrimidines\/pyridines as novel calcium-sensing receptor antagonists","volume":"52","author":"Yang","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0765","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1210\/en.2004-1318","article-title":"A novel calcium-sensing receptor antagonist transiently stimulates parathyroid hormone secretion in vivo","volume":"146","author":"Arey","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0770","doi-asserted-by":"crossref","first-page":"21558","DOI":"10.1074\/jbc.M603682200","article-title":"A missense mutation in the seven-transmembrane domain of the human Ca2+ receptor converts a negative allosteric modulator into a positive allosteric modulator","volume":"281","author":"Hu","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0775","doi-asserted-by":"crossref","first-page":"5161","DOI":"10.1016\/j.bmcl.2010.07.016","article-title":"Penta-substituted benzimidazoles as potent antagonists of the calcium-sensing receptor (CaSR-antagonists)","volume":"20","author":"Gerspacher","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0780","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1021\/jm051233+","article-title":"N1-Benzoyl-N2-[1-(1-naphthyl)ethyl]-trans-1,2-diaminocyclohexanes: development of 4-chlorophenylcarboxamide (Calhex 231) as a new calcium sensing receptor ligand demonstrating potent calcilytic activity","volume":"49","author":"Kessler","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0785","series-title":"Rational design of CaSR therapeutics for diverse disorders","author":"Leach","year":"2017"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0790","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1210\/jc.2010-2855","article-title":"The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density","volume":"96","author":"Fitzpatrick","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0795","doi-asserted-by":"crossref","first-page":"E2207","DOI":"10.1210\/jc.2013-4009","article-title":"A phase 2, randomized, placebo-controlled, dose-ranging study of the calcium-sensing receptor antagonist MK-5442 in the treatment of postmenopausal women with osteoporosis","volume":"99","author":"Halse","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0800","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00223-015-0052-z","article-title":"Calcimimetic and calcilytic drugs: feats, flops, and futures","volume":"98","author":"Nemeth","year":"2016","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0805","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrendo.2015.30","article-title":"The calcium-sensing receptor in bone\u2014mechanistic and therapeutic insights","volume":"11","author":"Goltzman","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0810","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3389\/fendo.2016.00172","article-title":"Review of hypoparathyroidism","volume":"7","author":"Abate","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0815","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(13)70106-2","article-title":"Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study","volume":"1","author":"Mannstadt","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0820","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1172\/JCI57407","article-title":"PTH-independent regulation of blood calcium concentration by the calcium-sensing receptor","volume":"122","author":"Loupy","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0825","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115178","article-title":"Amino alcohol (NPS 2143) and quinazolinones-derived calcilytics (AFT936 and AXT914) differentially mitigate excessive signalling of calcium-sensing receptor mutants causing Bartter syndrome type 5 and autosomal dominant hypocalcemia","volume":"9","author":"Letz","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0830","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1002\/jbmr.2551","article-title":"Calcilytic ameliorates abnormalities of mutant calcium-sensing receptor (CaSR) knock-in mice mimicking autosomal dominant hypocalcemia (ADH)","volume":"30","author":"Dong","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0835","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1210\/en.2015-1269","article-title":"The calcilytic agent NPS 2143 rectifies hypocalcemia in a mouse model with an activating calcium-sensing receptor (CaSR) mutation: relevance to autosomal dominant hypocalcemia type 1 (ADH1)","volume":"156","author":"Hannan","year":"2015","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/bs.pmch.2017.12.001_bb0840","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.91103","article-title":"G\u03b111 mutation in mice causes hypocalcemia rectifiable by calcilytic therapy","volume":"2","author":"Gorvin","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0845","doi-asserted-by":"crossref","first-page":"10876","DOI":"10.1074\/jbc.M115.696401","article-title":"Allosteric modulation of the calcium-sensing receptor rectifies signaling abnormalities associated with G-protein \u03b1-11 mutations causing hypercalcemic and hypocalcemic disorders","volume":"291","author":"Babinsky","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0850","article-title":"Treatment of autosomal dominant hypocalcemia with the calcilytic NPSP795","author":"Ramnitz","year":"2015","journal-title":"Ann Meet Am Soc Bone Min Res"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0855","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1210\/en.2017-00111","article-title":"Mutant mice with calcium-sensing receptor activation have hyperglycemia that is rectified by calcilytic therapy","volume":"158","author":"Babinsky","year":"2017","journal-title":"Endocrinology"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0860","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aaa0282","article-title":"Calcium-sensing receptor antagonists abrogate airway hyperresponsiveness and inflammation in allergic asthma","volume":"7","author":"Yarova","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0865","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1242\/dmm.003616","article-title":"Idiopathic pulmonary arterial hypertension","volume":"3","author":"Firth","year":"2010","journal-title":"Dis Model Mech"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0870","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1540\/jsmr.50.8","article-title":"Pathological function of Ca2+-sensing receptor in pulmonary arterial hypertension","volume":"50","author":"Yamamura","year":"2014","journal-title":"J Smooth Muscle Res"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0875","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/j.1582-4934.2007.00096.x","article-title":"Structure and function of the human calcium-sensing receptor: insights from natural and engineered mutations and allosteric modulators","volume":"11","author":"Hu","year":"2007","journal-title":"J Cell Mol Med"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0880","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/j.1476-5381.2009.00603.x","article-title":"Mechanisms of multimodal sensing by extracellular Ca2+-sensing receptors: a domain-based survey of requirements for binding and signalling","volume":"159","author":"Khan","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0885","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3389\/fphys.2016.00441","article-title":"Molecular basis of the extracellular ligands mediated signaling by the calcium sensing receptor","volume":"7","author":"Zhang","year":"2016","journal-title":"Front Physiol"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0890","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0026-895X(24)23025-X","article-title":"Domains determining ligand specificity for Ca2+ receptors","volume":"55","author":"Hammerland","year":"1999","journal-title":"Mol Pharmacol"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0895","doi-asserted-by":"crossref","first-page":"18382","DOI":"10.1074\/jbc.274.26.18382","article-title":"The agonist-binding domain of the calcium-sensing receptor is located at the amino-terminal domain","volume":"274","author":"Br\u00e4uner-Osborne","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0900","doi-asserted-by":"crossref","first-page":"32145","DOI":"10.1074\/jbc.M102977200","article-title":"Human Ca2+ receptor extracellular domain. Analysis of function of lobe 1 loop deletion mutants","volume":"276","author":"Reyes-Cruz","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0905","doi-asserted-by":"crossref","first-page":"46622","DOI":"10.1074\/jbc.M207100200","article-title":"Identification of acidic residues in the extracellular loops of the seven-transmembrane domain of the human Ca2+ receptor critical for response to Ca2+ and a positive allosteric modulator","volume":"277","author":"Hu","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0910","doi-asserted-by":"crossref","first-page":"18908","DOI":"10.1074\/jbc.M202113200","article-title":"Evidence for distinct cation and calcimimetic compound (NPS 568) recognition domains in the transmembrane regions of the human Ca2+ receptor","volume":"277","author":"Ray","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0915","doi-asserted-by":"crossref","first-page":"37917","DOI":"10.1074\/jbc.M506263200","article-title":"Delineating a Ca2+ binding pocket with the Venus flytrap module of the human calcium-sensing receptor","volume":"280","author":"Silve","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0920","doi-asserted-by":"crossref","first-page":"19000","DOI":"10.1074\/jbc.M701096200","article-title":"Identification and dissection of Ca2+-binding sites in the extracellular domain of Ca2+-sensing receptor","volume":"282","author":"Huang","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0925","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1021\/bi8014604","article-title":"Multiple Ca2+-binding sites in the extracellular domain of the Ca2+-sensing receptor corresponding to cooperative Ca2+ response","volume":"48","author":"Huang","year":"2009","journal-title":"Biochem"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0930","doi-asserted-by":"crossref","first-page":"33529","DOI":"10.1074\/jbc.M114.604652","article-title":"Direct determination of multiple ligand interactions with the extracellular domain of the calcium-sensing receptor","volume":"289","author":"Zhang","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0935","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1600241","article-title":"Structural basis for regulation of human calcium-sensing receptor by magnesium ions and an unexpected tryptophan derivative co-agonist","volume":"2","author":"Zhang","year":"2016","journal-title":"Sci Adv"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0940","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.13662","article-title":"Structural mechanism of ligand activation in human calcium-sensing receptor","volume":"5","author":"Geng","year":"2016","journal-title":"Elife"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0945","doi-asserted-by":"crossref","first-page":"51739","DOI":"10.1074\/jbc.M406164200","article-title":"The Venus fly trap domain of the extracellular Ca2+-sensing receptor is required for L-amino acid sensing","volume":"279","author":"Mun","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0950","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nature12725","article-title":"Structural mechanism of ligand activation in human GABA(B) receptor","volume":"504","author":"Geng","year":"2013","journal-title":"Nature"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0955","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1210\/endo.141.11.7753","article-title":"Effects of a calcimimetic compound and naturally activating mutations on the human Ca2+ receptor and on Ca2+ receptor\/metabotropic glutamate chimeric receptors","volume":"141","author":"Hauche","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0960","doi-asserted-by":"crossref","first-page":"37013","DOI":"10.1074\/jbc.M506681200","article-title":"Calindol, a positive allosteric modulator of the human Ca2+ receptor, activates an extracellular ligand-binding domain-deleted rhodopsin-like seven-transmembrane structure in the absence of Ca2+","volume":"280","author":"Ray","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0965","doi-asserted-by":"crossref","first-page":"7254","DOI":"10.1074\/jbc.M307191200","article-title":"Homology modeling of the transmembrane domain of the human calcium sensing receptor and localization of an allosteric binding site","volume":"279","author":"Miedlich","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0970","doi-asserted-by":"crossref","first-page":"18990","DOI":"10.1074\/jbc.M400724200","article-title":"Positive and negative allosteric modulators of the Ca2+ sensing receptor interact within overlapping but not identical binding sites in the transmembrane domain","volume":"279","author":"Petrel","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0975","doi-asserted-by":"crossref","first-page":"49487","DOI":"10.1074\/jbc.M308010200","article-title":"Modeling and mutagenesis of the binding site of Calhex 231, a novel negative allosteric modulator of the extracellular Ca2+-sensing receptor","volume":"278","author":"Petrel","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0980","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.tips.2015.02.004","article-title":"Towards tissue-specific pharmacology:insights from the calcium-sensing receptor as a paradigm for GPCR (patho)physiological bias","volume":"36","author":"Leach","year":"2015","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0985","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/cr.2016.36","article-title":"Towards a structural understanding of allosteric drugs at the human calcium-sensing receptor","volume":"26","author":"Leach","year":"2016","journal-title":"Cell Res"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0990","doi-asserted-by":"crossref","DOI":"10.1038\/srep46355","article-title":"Investigating the molecular mechanism of positive and negative allosteric modulators in the calcium-sensing receptor","volume":"7","author":"Jacobsen","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/bs.pmch.2017.12.001_bb0995","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/bph.12420","article-title":"Engendering biased signalling from the calcium-sensing receptor for the pharmacotherapy of diverse disorders","volume":"171","author":"Leach","year":"2014","journal-title":"Br J Pharmacol"},{"key":"10.1016\/bs.pmch.2017.12.001_bb1000","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1507\/endocrj.EJ13-0453","article-title":"Biased agonism: a novel paradigm in G protein-coupled receptor signaling observed in acquired hypocalciuric hypercalcemia","volume":"61","author":"Makita","year":"2014","journal-title":"Endocr J"},{"key":"10.1016\/bs.pmch.2017.12.001_bb1005","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0031-6997(25)06948-0","article-title":"The classification of seven transmembrane receptors in recombinant expression systems","volume":"48","author":"Kenakin","year":"1996","journal-title":"Pharmacol Rev"},{"key":"10.1016\/bs.pmch.2017.12.001_bb1010","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/bph.12937","article-title":"Biased allosteric modulation at the CaS receptor engendered by structurally diverse calcimimetics","volume":"172","author":"Cook","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1016\/bs.pmch.2017.12.001_bb1015","series-title":"Animal farm","first-page":"112","author":"Orwell","year":"1946"}],"container-title":["Progress in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S007964681730022X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S007964681730022X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T15:40:34Z","timestamp":1751470834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S007964681730022X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9780128152133"],"references-count":202,"URL":"https:\/\/doi.org\/10.1016\/bs.pmch.2017.12.001","relation":{},"ISSN":["0079-6468"],"issn-type":[{"value":"0079-6468","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}